CN1315841C - An improved process for the preparation of chloro methyl cephem derivatives - Google Patents

An improved process for the preparation of chloro methyl cephem derivatives Download PDF

Info

Publication number
CN1315841C
CN1315841C CNB2003801023937A CN200380102393A CN1315841C CN 1315841 C CN1315841 C CN 1315841C CN B2003801023937 A CNB2003801023937 A CN B2003801023937A CN 200380102393 A CN200380102393 A CN 200380102393A CN 1315841 C CN1315841 C CN 1315841C
Authority
CN
China
Prior art keywords
formula
solvent
salt
sulfinic acid
alkali
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2003801023937A
Other languages
Chinese (zh)
Other versions
CN1708501A (en
Inventor
S·尤达亚姆帕拉亚姆帕拉尼萨米
P·B·戴什潘德
S·N·卡拉勒
P·拉玛尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orchid Pharma Ltd
Original Assignee
Orchid Chemicals and Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orchid Chemicals and Pharmaceuticals Ltd filed Critical Orchid Chemicals and Pharmaceuticals Ltd
Publication of CN1708501A publication Critical patent/CN1708501A/en
Application granted granted Critical
Publication of CN1315841C publication Critical patent/CN1315841C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/02Preparation
    • C07D501/08Preparation by forming the ring or condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

The present invention provides an improved process to produce the chloromethylcephem derivatives of the formula (I), wherein R<1> represents a carboxy-protecting group viz., substituted methyl group, which can be deprotected easily, such as t-butyl group, diphenylmethyl, 4-methoxybenzyl, 2-methoxybenzyl, 2-chlorobenzyl or benzyl group; R<2> represents hydrogen, (C<1>-C<4>)alkyl, substituted or unsubstituted phenyl or substituted or unsubstituted phenoxy group.

Description

Improving one's methods of preparation chloromethyl cephalosporin ene derivative
Invention field
The invention provides the method for chloromethyl cephalosporin alkene (cephem) derivative of a kind of improved preparation formula (I):
Figure C20038010239300051
R wherein 1The expression carboxy protective group, that is, the methyl of replacement, it is deprotection easily, such as the tertiary butyl, diphenyl-methyl, 4-methoxybenzyl, 2-methoxybenzyl, 2-benzyl chloride base or benzyl; R 2Expression hydrogen, (C 1-C 4) alkyl, replacement or unsubstituted phenyl or replacement or unsubstituted phenoxy.
The chloromethyl cephalosporin ene derivative of prepared according to the methods of the invention formula (I) can be used for the cephalosporin antibiotics of preparation formula (II):
R wherein 4Be carboxylic acid ion or COOR d, R wherein dExpression hydrogen, ester or the salifiable counter ion of shape; R 6Expression H, CH 3, CR aR bCOOR c, R wherein aAnd R bRepresent hydrogen or methyl independently, R cExpression hydrogen or (C 1-C 6) alkyl; R 5Expression CH 3, CH 2OCH 3, CH 2OCOCH 3, CH=CH 2, or
The cephalosporin antibiotics of formula (II) has wide biological activity.Specifically, the cephalosporin antibiotics of formula (II) has the excellent antibiotic activity.
Background of invention
In view of the importance that the key intermediate of multiple cephalosporin medicament is synthesized in the 3-chloromethyl cephalosporin alkene conduct of formula (I), various preparation methods (US4,853,468 have been reported; US4,789,740).In most of the cases, the alkylsulfonyl aza cyclo-butanone derivatives of formula (III) is carried out allyl type/alkene type chlorination, obtain the chloro azetidinone of formula (IV) with various chlorizating agents such as chlorine, chlorine monoxide etc.The chloro azetidinone of formula (IV) further at low temperatures, cyclisation in the presence of alkali obtains the chloromethyl cephalosporin alkene of formula (I):
R wherein 1And R 2Definition as above; R 3Expression phenyl, (C 1-C 4) alkyl phenyl, (C 1-C 4) alkoxyl phenyl or heteroaryl.
The preparation of alkylsulfonyl azetidinone intermediate, as by reported method it being prepared, invariably accompanying forms a large amount of impurity, causes the purity of alkylsulfonyl azetidinone lower, and this makes the yield of chloromethyl cephalosporin alkene of formula (I) low conversely.
In addition, the by product that forms in the process of preparation alkylsulfonyl azetidinone intermediate can not be removed fully by existing acetone system; And if this by product do not remove in this step, it will cause forming more impurity in the conversion of next step chlorination and cyclisation.Therefore, need find a kind of method, this method can be with respect to by product is removed away from alkylsulfonyl azetidinone intermediate.
In addition, carry out in last step of cyclisation with ammonia in DMF, we find that the formation degree of impurity is very high in the process that adds alkali.This just need develop the method that alternate can provide better conversion and therefore better yield is arranged.
Constantly make great efforts and deep research through us, we have determined a kind of method of cleaning at last, and it can solve above-mentioned all restrictions, and the chloromethyl cephalosporin ene derivative of production (I).
Goal of the invention
Main purpose of the present invention is that a kind of simply and effectively method of the chloromethyl cephalosporin ene derivative of the 3-chloromethyl azetidinone compounds preparation formula (I) of through type (VII) is provided.
Another object of the present invention is, the method for the chloromethyl azetidinone compounds of a kind of preparation formula (VII) is provided, and do not use reluctant dangerous reagent in industrial scale in the method.
Another object of the present invention is that the mode by the formation of control major impurity with a kind of cleaning prepares the alkylsulfonyl azetidinone, and the method for removing by product is provided.
Another object of the present invention is, the chloromethyl azetidinone compounds of a kind of cyclisation formula (VII) is provided, and simultaneously minimum level reduced in the formation of impurity and obtained the method for peak rate of conversion.
Summary of the invention
Therefore, the invention provides the method for the chloromethyl cephalosporin ene derivative of a kind of improved preparation formula (I),
Figure C20038010239300071
R wherein 1The expression carboxy protective group, that is, the methyl of replacement, it is deprotection easily, such as the tertiary butyl, diphenyl-methyl, 4-methoxybenzyl, 2-methoxybenzyl, 2-benzyl chloride base or benzyl; R 2Expression hydrogen, (C 1-C 4) alkyl, replacement or unsubstituted phenyl or replacement or unsubstituted phenoxy, said method comprising the steps of:
(i) use aryl-sulfinic acid or (C 1-C 6) metal-salt, alkali and the solvent of alkyl sulfinic acid, in 25 ℃-40 ℃ temperature range, the compound of formula V is converted into the compound of formula (VI), wherein R 8Expression replaces or unsubstituted (C 1-C 6) alkyl or aryl, wherein improve the metal-salt that adds the aryl-sulfinic acid in the pH value scope that is included in 4-8.0,
(ii) in the presence of alkali and solvent, in 15 ℃-40 ℃ temperature range, use the compound of chlorizating agent chlorination formula (VI), obtain the compound of formula (VII), wherein R 8Expression replaces or unsubstituted (C 1-C 6) alkyl or aryl, every other symbol definition as above and
(vi) in solvent, in-60 ℃ to+50 ℃ temperature range, use the compound cyclisation of alkali, obtain the chloromethyl cephalosporin ene derivative of formula (I) formula (VII).
The synthetic method of the chloromethyl cephalosporin ene derivative of formula (I) is shown in scheme-I.
Scheme-1
Figure C20038010239300081
R wherein 1And R 2Definition as above.
Invention is described
In embodiments of the invention, by R 7The heteroaryl of expression is selected from 2-mercaptobenzothiazole, 2-sulfydryl benzo _ azoles, 2-mercaptobenzimidazole or 2-sulfydryl-5-methyl tetrazolium.
In another embodiment of the invention, the conversion of step (i) be selected from acetone, THF, dioxane, diglyme, methylethylketone, acetonitrile, such as the alcohol of methyl alcohol, ethanol or Virahol in the presence of, with being selected from toluenesulfinic acid copper (II), benzene sulfinic acid copper (II), the aryl-sulfinic acid metal-salt of toluenesulfinic acid silver (II), benzene sulfinic acid silver (II) etc. being carried out, be with or without water and all can.
In another embodiment of the present invention, when step (i) is carried out, use alkali that the pH value is controlled in the 4-8 scope, more preferably 5-7, described alkali are selected from ammonia, alkali/alkaline earth metal carbonate such as lime carbonate, sodium bicarbonate, yellow soda ash, salt of wormwood, saleratus or such as the organic bases of diisopropylethylamine, triethylamine etc.
In another embodiment of the invention, be used for step chlorizating agent (ii) and be selected from chlorine, HOCl, Cl in the presence of alkali 2O, CH 3OCl etc.
In another embodiment of the invention, be used for step (ii) chlorizating agent or use with the form of gas, perhaps use with the solution form in solvent, described solvent is selected from dioxane, tetracol phenixin, ethyl acetate, acetonitrile, diglyme, N,N-DIMETHYLACETAMIDE, tetrahydrofuran (THF), methylene dichloride, butylacetate, phenyl ether, toluene or its mixture.
In another embodiment of the invention, be used for step alkali (ii) and be selected from alkali/alkaline earth metal carbonate such as lime carbonate, sodium bicarbonate, yellow soda ash, salt of wormwood, saleratus etc.
In another embodiment of the present invention, step cyclisation (iii) uses alkali to carry out, and described alkali is selected from ammonia, ammonium salt such as volatile salt, ammonium acetate, organic amine such as Diisopropylamine, quadrol, diethylamine, methylamine, triethylamine etc.
In another embodiment of the present invention; step cyclisation is (iii) carried out in solvent, and described solvent is selected from DMF, acetonitrile, N,N-DIMETHYLACETAMIDE, ethyl acetate, 4-formyl morpholine, 4-ethanoyl morpholine, dioxane, methyl-sulphoxide, THF, 1-methylpyrrolidin-2-ketone (NMP), methylene dichloride etc. or its mixture.
In another embodiment of the invention, raw material can prepare with the known literature method of prior art.
From industry, technology and ecological angle, it is attractive that aforesaid method has been considered to, and can obtain the chloromethyl aza cyclo-butanone derivatives of formula (VII).
Can obtain many other beneficial effects by using disclosed invention in a different manner or in the scope of disclosure, the present invention being carried out modification.
The present invention describes by following examples, and it should not be considered to be limiting the scope of the invention.
Embodiment 1:
Step-1
2-(2-[4-morpholinodithio base dithio)-α-(1-methyl ethylene)-4-oxo-3-phenylacetylamino-1-azetidine acetate is to methoxybenzyl ester (V)
Under 27 ℃ and nitrogen atmosphere, add 6-phenylacetylamino penicillanic acid in the dry toluene that in the round-bottomed flask that the Dean-Stark water trap is housed, is comprised (500 milliliters) to methoxybenzyl ester-1-oxide compound (25 gram) and 2-mercaptobenzothiazole (8.9 restrain).Reaction mixture refluxed heating 30 minutes, and under reflux temperature, kept 5 hours.After reaction finished, solvent removed in vacuo obtained that 2-(2-[4-morpholinodithio base dithio)-α-(1-methyl ethylene)-4-oxo-3-phenylacetylamino-1-azetidine acetate is to the methoxybenzyl ester, and it is used to carry out next step.
Step-2
2-(p-toluenesulfonyl sulfo-)-α-(1-methyl ethylene)-4-oxo-3-phenylacetylamino-1-azetidine acetate is to the preparation of methoxybenzyl ester (VI)
Under agitation, to 2-(2-[4-morpholinodithio base dithio)-α-(1-methyl ethylene)-4-oxo-3-phenylacetylamino-1-azetidine acetate to methoxybenzyl ester (methoxybenzyl ester-1-oxide compound being obtained) by 25 gram 6-phenylacetylamino penicillanic acids in adding acetone (220 milliliters), obtain 28-30 ℃ clear solution, and be cooled to 20-25 ℃.Under this temperature, under agitation add entry (32 milliliters).With saturated sodium hydrogen carbonate solution the pH value of solution is adjusted to 6.0-7.0.In 90-120 minute, under 20-25 ℃, in the solution that stirs, add toluenesulfinic acid copper (II) (13.0 gram) in batches, with saturated sodium hydrogen carbonate solution the pH value is remained on 5.5-6.5 simultaneously.After reaction finished, reaction mixture filtered by the hyflo bed, this bed washing with acetone.Filtrate vacuum concentration in rotatory evaporator, remove and desolvate.In the material of remnants, add ethyl acetate (125 milliliters) and water (125 milliliters), stirred 5-10 minute, add sodium-chlor subsequently.The separation organic layer also washes with water twice.Organic layer is at<25 ℃ of following vacuum concentration, up to obtaining pasty substance.Add methyl alcohol, obtain slurries 28-30 ℃ of stirring, and be cooled to 2-5 ℃.Slurries were stirred 1 hour under this temperature, filter and with cold methanol wash.This filtrate is at<25 ℃ of following vacuum concentration, obtains that 2-(p-toluenesulfonyl sulfo-)-α-(1-methyl ethylene)-4-oxo-3-phenylacetylamino-1-azetidine acetate is to the methoxybenzyl ester, and it is used for next step under situation about not being further purified.(HPLC purity is 89-90%).
Step-3
2-(p-toluenesulfonyl sulfo-)-α-(1-chloromethyl vinyl)-4-oxo-3-phenylacetylamino-1-azetidine acetate is to the preparation of methoxybenzyl ester (VII)
At 26-28 ℃; with 1; 4-dioxane (150 milliliters) join above 2-(p-toluenesulfonyl sulfo-)-α-(1-methyl ethylene)-4-oxo-3-phenylacetylamino-1-azetidine acetate to the methoxybenzyl ester (shown in step-2; by 25 gram 6-phenylacetylamino penicillanic acids methoxybenzyl ester-1-oxide compound is obtained) in, add sodium bicarbonate (90 gram) subsequently.Add Cl at leisure 2/ CCl 4(12.5%w/v) (60 milliliters).After reaction finishes, reaction mixture is filtered and wash with methylene dichloride (150 milliliters).In filtrate, add cold water (450 milliliters), separate organic layer, wash with water subsequently with hypo solution earlier.The organic layer activated carbon treatment; concentrate and use the method in common aftertreatment; obtain 2-(p-toluenesulfonyl sulfo-)-α-(1-chloromethyl vinyl)-4-oxo-3-phenylacetylamino-1-azetidine acetate to the methoxybenzyl ester, it is not purified just to be used to carry out next step.
Step-4
7-phenylacetylamino-3-chloromethyl-3-cephem-4-carboxylic acid is to the preparation of methoxybenzyl ester (I)
Under 28-30 ℃; add 1-methylpyrrolidin-2-ketone (125 milliliters) to 2-(p-toluenesulfonyl sulfo-)-α-(1-chloromethyl vinyl)-4-oxo-3-phenylacetylamino-1-azetidine acetate in to methoxybenzyl ester (methoxybenzyl ester-1-oxide compound being obtained), and stirring obtains clear solution by 25 gram 6-phenylacetylamino penicillanic acids.In this solution, add methylene dichloride (50 milliliters) and be cooled to-50 ℃ to-40 ℃.Under-50 ℃, in 2-5 minute, in this reaction mixture, be added in the ammonia soln in the 1-methylpyrrolidin-2-ketone (25 milliliters, 2-5 ℃), raise the temperature to-40 ℃.Reaction mixture was stirred 15-20 minute down at-45 ℃ to-40 ℃.Under-50 ℃ to-40 ℃, in 5 minutes, in this reaction mixture, dripped cold dilute hydrochloric acid (1: 1; 27 milliliters; 2-5 ℃).Reaction mixture is poured in 2-5 ℃ the cold water (900 milliliters).Add methylene dichloride, stirred 5-10 minute, separate organic layer.Water layer is further used dichloromethane extraction.Merge organic layer, and with 5-10 ℃ cold water washing 4 times.Remove fully in<20 ℃ of following vacuum and to desolvate.Under 28-30 ℃, in the material of remnants, add methyl alcohol (175 milliliters), stirred 10-15 minute, obtain slurries and be cooled to 3-5 ℃.Slurries were stirred 1 hour under this temperature, filter and with cold methanol wash.With the material vacuum-drying that obtains like this 4-5 hour, obtain 7-phenylacetylamino-3-chloromethyl-3-cephem-4-carboxylic acid to methoxybenzyl ester, colorless solid.(15.1 gram).
Embodiment 2:
Step-1
2-(2-[4-morpholinodithio base dithio)-α-(1-methyl ethylene)-4-oxo-3-phenylacetylamino-1-azetidine acetate is to the preparation of methoxybenzyl ester (V)
Under 27 ℃ and nitrogen atmosphere, add 6-phenylacetylamino penicillanic acid in the dry toluene that in the round-bottomed flask that the Dean-Stark water trap is housed, is comprised (500 milliliters) to methoxybenzyl ester-1-oxide compound (25 gram) and 2-mercaptobenzothiazole (8.9 restrain).Reaction mixture refluxed heating 30 minutes also keeps 5 hours (this reaction also can be carried out as solvent with dioxane) under reflux temperature.After reaction finished, solvent removed in vacuo obtained that 2-(2-[4-morpholinodithio base dithio)-α-(1-methyl ethylene)-4-oxo-3-phenylacetylamino-1-azetidine acetate is to the methoxybenzyl ester, and it is used to carry out next step.
Step-2
2-(p-toluenesulfonyl sulfo-)-α-(1-methyl ethylene)-4-oxo-3-phenylacetylamino-1-azetidine acetate is to the preparation of methoxybenzyl ester
Under agitation, to 2-(2-[4-morpholinodithio base dithio)-α-(1-methyl ethylene)-4-oxo-3-phenylacetylamino-1-azetidine acetate to methoxybenzyl ester (methoxybenzyl ester-1-oxide compound being obtained) by 25 gram 6-phenylacetylamino penicillanic acids in adding acetone (220 milliliters), obtain 28-30 ℃ clear solution, and be cooled to 20-25 ℃.Under this temperature, under agitation add entry (32 milliliters).With saturated sodium hydrogen carbonate solution the pH value of solution is adjusted to 6.0-7.0.In 90-120 minute, under 20-25 ℃, in the solution that stirs, add toluenesulfinic acid copper (II) (13.0 gram) in batches, with saturated sodium hydrogen carbonate solution the pH value is remained on 5.5-6.5 simultaneously.After reaction finished, reaction mixture filtered by the hyflo bed, this bed washing with acetone.The filtrate vacuum concentration, in rotatory evaporator, remove and desolvate.In the material of remnants, add ethyl acetate (125 milliliters) and water (125 milliliters), stirred 5-10 minute, add sodium-chlor subsequently.The separation organic layer also washes with water twice.Organic layer is at<25 ℃ of following vacuum concentration, up to obtaining pasty substance.Add methyl alcohol, obtain slurries 28-30 ℃ of stirring, and be cooled to 2-5 ℃.Slurries were stirred 1 hour under this temperature, filter and with cold methanol wash.This filtrate is at<25 ℃ of following vacuum concentration, obtains that 2-(p-toluenesulfonyl sulfo-)-α-(1-methyl ethylene)-4-oxo-3-phenylacetylamino-1-azetidine acetate is to the methoxybenzyl ester, and it is used for next step under situation about not being further purified.(HPLC purity is 89-90%).
Step-3
2-(p-toluenesulfonyl sulfo-)-α-(1-chloromethyl vinyl)-4-oxo-3-phenylacetylamino-1-azetidine acetate is to the preparation of methoxybenzyl ester
At 26-28 ℃; with 1; 4-dioxane (150 milliliters) join above 2-(p-toluenesulfonyl sulfo-)-α-(1-methyl ethylene)-4-oxo-3-phenylacetylamino-1-azetidine acetate to the methoxybenzyl ester (shown in step-2; by 25 gram 6-phenylacetylamino penicillanic acids methoxybenzyl ester-1-oxide compound is obtained) in, add sodium bicarbonate (90 gram) subsequently.Add Cl at leisure 2/ CCl 4(12.5%w/v) (60 milliliters).After reaction finishes, reaction mixture is filtered and wash with methylene dichloride (150 milliliters).In filtrate, add cold water (450 milliliters), separate organic layer, wash with water subsequently with hypo solution earlier.The organic layer activated carbon treatment; concentrate and use the method in common aftertreatment; obtain 2-(p-toluenesulfonyl sulfo-)-α-(1-chloromethyl vinyl)-4-oxo-3-phenylacetylamino-1-azetidine acetate to the methoxybenzyl ester, it is not purified just to be used to carry out next step.
Step-4
7-phenylacetylamino-3-chloromethyl-3-cephem-4-carboxylic acid is to the preparation of methoxybenzyl ester
Join the 2-that obtains according to step-3 among the above embodiment-1 (p-toluenesulfonyl sulfo-)-α-(1-chloromethyl vinyl)-4-oxo-3-phenylacetylamino-1-azetidine acetate among the DMF (125 milliliters) to methoxybenzyl ester (methoxybenzyl ester-1-oxide compound being obtained) and be cooled to-40 ℃ by 25 gram 6-phenylacetylamino penicillanic acids.Add the solution of ammonia (11.5 milliliters) in DMF, and keep this temperature to finish up to reaction.With reaction mixture dilute hydrochloric acid acidifying, filter.The solid that obtains is used DMF in the presence of gac: methyl alcohol (2: 9) extraction, and concentrate and handle with cold methanol, obtain 7-phenylacetylamino-3-chloromethyl-3-cephem-4-carboxylic acid to methoxybenzyl ester (13.6 gram).
The comparative example 3:
Step-1
2-(2-[4-morpholinodithio base dithio)-α-(1-methyl ethylene)-4-oxo-3-phenylacetylamino-1-azetidine acetate is to the preparation of methoxybenzyl ester (V)
Under 27 ℃ and nitrogen atmosphere, add 6-phenylacetylamino penicillanic acid in the dry toluene that in the round-bottomed flask that the Dean-Stark water trap is housed, is comprised (500 milliliters) to methoxybenzyl ester-1-oxide compound (25 gram) and 2-mercaptobenzothiazole (8.9 restrain).Reaction mixture refluxed heating 30 minutes also keeps 5 hours (this reaction also can be carried out as solvent with dioxane) under reflux temperature.After reaction finished, solvent removed in vacuo obtained that 2-(2-[4-morpholinodithio base dithio)-α-(1-methyl ethylene)-4-oxo-3-phenylacetylamino-1-azetidine acetate is to the methoxybenzyl ester, and it is used to carry out next step.
Step-2
2-(p-toluenesulfonyl sulfo-)-α-(1-methyl ethylene)-4-oxo-3-phenylacetylamino-1-azetidine acetate is to the preparation of methoxybenzyl ester (VI)
Under agitation, to 2-(2-[4-morpholinodithio base dithio)-α-(1-methyl ethylene)-4-oxo-3-phenylacetylamino-1-azetidine acetate to methoxybenzyl ester (methoxybenzyl ester-1-oxide compound being obtained) by 25 gram 6-phenylacetylamino penicillanic acids in adding acetone (220 milliliters), obtain 28-30 ℃ clear solution, and be cooled to 20-25 ℃.Under this temperature, under agitation add entry (32 milliliters).In 90-120 minute, under 20-25 ℃, in the solution that stirs, add toluenesulfinic acid copper (II) (12.8 gram) in batches.After reaction finished, reaction mixture filtered by the hyflo bed, this bed washing with acetone.The filtrate vacuum concentration, in rotatory evaporator, remove and desolvate.In the material of remnants, add ethyl acetate (125 milliliters) and water (125 milliliters), stirred 5-10 minute, add sodium-chlor subsequently.The separation organic layer also washes with water twice.Organic layer is at<25 ℃ of following vacuum concentration, up to obtaining pasty substance.Add methyl alcohol, obtain slurries 28-30 ℃ of stirring, and be cooled to 2-5 ℃.Slurries were stirred 1 hour under this temperature, filter and with cold methanol wash.This filtrate is at<25 ℃ of following vacuum concentration, obtains that 2-(p-toluenesulfonyl sulfo-)-α-(1-methyl ethylene)-4-oxo-3-phenylacetylamino-1-azetidine acetate is to the methoxybenzyl ester, and it is used for next step under situation about not being further purified.(HPLC purity: 75-80%)
Step-3
2-(p-toluenesulfonyl sulfo-)-α-(1-chloromethyl vinyl)-4-oxo-3-phenylacetylamino-1-azetidine acetate is to the preparation of methoxybenzyl ester (VII)
At 26-28 ℃; with 1; 4-dioxane (150 milliliters) join above 2-(p-toluenesulfonyl sulfo-)-α-(1-methyl ethylene)-4-oxo-3-phenylacetylamino-1-azetidine acetate to the methoxybenzyl ester (shown in step-2; by 25 gram 6-phenylacetylamino penicillanic acids methoxybenzyl ester-1-oxide compound is obtained) in, add sodium bicarbonate (90 gram) subsequently.Add Cl at leisure 2/ CCl 4(12.5%w/v) (60 milliliters).After reaction finishes, reaction mixture is filtered and wash with methylene dichloride (150 milliliters).In filtrate, add cold water (450 milliliters), separate organic layer, wash with water subsequently with hypo solution earlier.The organic layer activated carbon treatment; concentrate and use the method in common aftertreatment; obtain 2-(p-toluenesulfonyl sulfo-)-α-(1-chloromethyl vinyl)-4-oxo-3-phenylacetylamino-1-azetidine acetate to the methoxybenzyl ester, it is not purified just to be used to carry out next step.
Step-4
7-phenylacetylamino-3-chloromethyl-3-cephem-4-carboxylic acid is to the preparation of methoxybenzyl ester
Join the 2-that obtains according to step-3 among the above embodiment-1 (p-toluenesulfonyl sulfo-)-α-(1-chloromethyl vinyl)-4-oxo-3-phenylacetylamino-1-azetidine acetate among the DMF (125 milliliters) to methoxybenzyl ester (methoxybenzyl ester-1-oxide compound being obtained) and be cooled to-40 ℃ by 25 gram 6-phenylacetylamino penicillanic acids.Add the solution of ammonia (11.5 milliliters) in DMF, and keep this temperature to finish up to reaction.With reaction mixture dilute hydrochloric acid acidifying, filter.The solid that obtains is used DMF in the presence of gac: methyl alcohol (2: 9) extraction, and concentrate and handle with cold methanol, obtain 7-phenylacetylamino-3-chloromethyl-3-cephem-4-carboxylic acid to methoxybenzyl ester (11.4 gram).
Beneficial effect:
The comparison of embodiment
Embodiment 1 Embodiment 2 The comparative example 3
The HPLC purity of step 2 89-90% 89-90% 75-80%
Yield (methoxybenzyl ester-1-oxide compound being begun to calculate) by 25 gram 6-phenylacetylamino penicillanic acids 15.1 gram 13.6 gram 11.4 gram
The solvent that uses in the step 3 NMP DMF DMF
Can draw from this table,
* in step process (ii), adjust the purity that the pH value has increased 2-(p-toluenesulfonyl sulfo-)-α-(1-methyl ethylene)-4-oxo-3-phenylacetylamino-1-azetidine acetic ester.
When * cyclisation step is used NMP, compare with DMF, yield is higher.

Claims (10)

1. the method for the chloromethyl cephalosporin ene derivative of an improved preparation formula (I),
R wherein 1Expression is selected from the carboxy protective group of the tertiary butyl, diphenyl-methyl, 4-methoxybenzyl, 2-methoxybenzyl, 2-benzyl chloride base or benzyl; R 2Expression hydrogen, (C 1-C 4) alkyl, replacement or unsubstituted phenyl or replacement or unsubstituted phenoxy, said method comprising the steps of:
(i) use aryl-sulfinic acid or (C 1-C 6) metal-salt, alkali and the solvent of alkyl sulfinic acid, in 25 ℃-40 ℃ temperature range with the compound of formula V
Figure C2003801023930002C2
Be converted into the compound of formula (VI),
Figure C2003801023930002C3
R wherein 8Expression replaces or unsubstituted (C 1-C 6) alkyl or aryl, wherein improve the metal-salt that adds the aryl-sulfinic acid in the pH value scope that is included in 4.0-8.0,
(ii) in the presence of alkali and solvent, in 15 ℃-40 ℃ temperature range, use the compound of chlorizating agent chlorination formula (VI), obtain the compound of formula (VII),
R wherein 8Expression replaces or unsubstituted (C 1-C 6) alkyl or aryl, every other symbol definition as above and
(vi) in solvent, in-60 ℃ to+50 ℃ temperature range, use the compound cyclisation of alkali, obtain the chloromethyl cephalosporin ene derivative of formula (I) formula (VII).
2. according to the process of claim 1 wherein that the aryl-sulfinic acid metal-salt that uses in the step (i) is selected to toluenesulfinic acid copper (II), benzene sulfinic acid copper (II), benzene sulfinic acid sodium salt, to toluenesulfinic acid silver (II) or benzene sulfinic acid silver (II).
According to the process of claim 1 wherein the solvent that uses in the step (i) be selected from acetone, THF, dioxane, acetonitrile, such as the alcohol of methyl alcohol, ethanol or Virahol, be with or without water and all can.
4. according to the process of claim 1 wherein middle aryl-sulfinic acid or the (C of adding of step (i) 1-C 6) metal-salt of alkyl sulfinic acid preferably carries out under the pH of 5-7 value.
5. according to the process of claim 1 wherein that the middle alkali that uses of step (i) is selected from ammonia, lime carbonate, sodium bicarbonate, yellow soda ash, salt of wormwood, saleratus, diisopropylethylamine or triethylamine.
6. according to the process of claim 1 wherein that the chlorizating agent that uses during step (ii) is selected from the presence of the solvent or the chlorine in the presence of solvent-free, HOCl, Cl 2O, CH 3OCl.
7. according to the method for claim 6, wherein chlorizating agent is dissolved in dioxane, tetracol phenixin, ethyl acetate, acetonitrile, diglyme, dimethyl formamide, N,N-DIMETHYLACETAMIDE, tetrahydrofuran (THF), methylene dichloride, butylacetate, phenyl ether, toluene or its mixture.
8. according to the process of claim 1 wherein that the (ii) middle solvent that uses of step is selected from dioxane, tetracol phenixin, ethyl acetate, acetonitrile, diglyme, N,N-DIMETHYLACETAMIDE, tetrahydrofuran (THF), methylene dichloride, butylacetate, phenyl ether, toluene or its mixture.
9. according to the process of claim 1 wherein that step cyclisation use alkali (iii) carries out, described alkali is selected from ammonia, ammonium salt such as volatile salt, ammonium acetate, organic amine such as N, N-Diisopropylamine, N, N dimethylamine, methylamine or triethylamine.
10. according to the process of claim 1 wherein that the (iii) middle solvent that uses of step is selected from 1-methylpyrrolidin-2-ketone (NMP), DMF, acetonitrile, N,N-DIMETHYLACETAMIDE, ethyl acetate, dioxane, THF, methylene dichloride.
CNB2003801023937A 2002-11-01 2003-10-23 An improved process for the preparation of chloro methyl cephem derivatives Expired - Fee Related CN1315841C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN808CH2002 2002-11-01
IN808/MAS/2002 2002-11-01

Publications (2)

Publication Number Publication Date
CN1708501A CN1708501A (en) 2005-12-14
CN1315841C true CN1315841C (en) 2007-05-16

Family

ID=35561711

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2003801023937A Expired - Fee Related CN1315841C (en) 2002-11-01 2003-10-23 An improved process for the preparation of chloro methyl cephem derivatives

Country Status (5)

Country Link
JP (1) JP2006507289A (en)
KR (1) KR20050087791A (en)
CN (1) CN1315841C (en)
AU (1) AU2003269416A1 (en)
WO (1) WO2004039813A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005026176A1 (en) * 2003-09-09 2005-03-24 Nippon Chemical Industrial Co.,Ltd. Process for producing 3-chloromethyl-3-cephem derivative
CN101260116A (en) * 2008-04-21 2008-09-10 湖南有色凯铂生物药业有限公司 Method for synthesizing 7-phenylacetamide-3-chloromethyl-4-cephalosporanic acid p-methoxybenzyl ester
CN102344459B (en) * 2011-07-27 2014-08-06 山西新天源医药化工有限公司 Preparation method of cephalosporin intermediate GCLE
CN102643294B (en) * 2012-04-18 2014-11-26 山东普洛得邦医药有限公司 Preparation method of cephalosporin nucleus intermediate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4789740A (en) * 1983-03-10 1988-12-06 Otsuka Kagaku Yakuhin Kabushiki Kaisha Halogenation process for preparing 2-(oxoazetidinyl)-3-chloromethyl-3-butenoate
US4853468A (en) * 1981-04-10 1989-08-01 Otsuka Kagaku Yakuhin Kabushiki Kaisha Process for the preparation of cephem derivatives
EP0623622A1 (en) * 1992-07-27 1994-11-09 Otsuka Kagaku Kabushiki Kaisha Process for producing cephem compound
WO1998055485A1 (en) * 1997-06-04 1998-12-10 Otsuka Kagaku Kabushiki Kaisha Process for producing 3-alkenylcephem compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE35152B1 (en) * 1969-08-26 1975-11-26 Glaxo Lab Ltd Improvements in or relating to cephalosporin compounds
NL7411505A (en) * 1973-09-06 1975-03-10 Rhone Poulenc Sa PROCEDURE FOR THE PREPARATION AND USE OF NEW 7-TRICHLORACETAMIDO-3-DESACETOXY-CEFA-LOSPORANIC ACID PREPARATIONS.
AU498131B2 (en) * 1974-02-26 1979-02-15 Ciba-Geigy Ag Production of cephems by cyclization
JPS6043340B2 (en) * 1981-04-10 1985-09-27 大塚化学薬品株式会社 Chlorinated azetidinone derivatives and their production method
JPS5874689A (en) * 1981-10-29 1983-05-06 Otsuka Chem Co Ltd Preparation of 3-chloromethyl-3-cephem derivative
JPS60237061A (en) * 1984-05-08 1985-11-25 Otsuka Chem Co Ltd Preparation of azetidinone derivative
JPS60115562A (en) * 1983-11-28 1985-06-22 Otsuka Chem Co Ltd Production of azetidinone derivative
DE3933934A1 (en) * 1989-10-03 1991-04-11 Bayer Ag METHOD FOR PRODUCING 7-AMINO-3 - ((Z) -1-PROPEN-1-YL) -3-CEPHEM-4-CARBONIC ACID

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853468A (en) * 1981-04-10 1989-08-01 Otsuka Kagaku Yakuhin Kabushiki Kaisha Process for the preparation of cephem derivatives
US4789740A (en) * 1983-03-10 1988-12-06 Otsuka Kagaku Yakuhin Kabushiki Kaisha Halogenation process for preparing 2-(oxoazetidinyl)-3-chloromethyl-3-butenoate
EP0623622A1 (en) * 1992-07-27 1994-11-09 Otsuka Kagaku Kabushiki Kaisha Process for producing cephem compound
WO1998055485A1 (en) * 1997-06-04 1998-12-10 Otsuka Kagaku Kabushiki Kaisha Process for producing 3-alkenylcephem compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
COPPER(I) BENZENESULFINATE AND COPPER(I)P-TOLUENESULFINATE BERTZ ET AL:,INORGANIC CHEMISTRY,Vol.24 No.21 1985 *

Also Published As

Publication number Publication date
WO2004039813A1 (en) 2004-05-13
JP2006507289A (en) 2006-03-02
KR20050087791A (en) 2005-08-31
CN1708501A (en) 2005-12-14
AU2003269416A1 (en) 2004-05-25

Similar Documents

Publication Publication Date Title
CN102002060B (en) Preparation method of cefozopran hydrochloride
CN1315841C (en) An improved process for the preparation of chloro methyl cephem derivatives
US7741478B2 (en) Salts in the preparation of cephalosporin antibiotics
CN102633819A (en) Preparation method of cefoxitin
JP3751880B2 (en) Method for producing high-purity cefpodoxime proxetil
WO2006067803A1 (en) A novel intermediate for the preparation of cefepime
CN1520418A (en) Process for prepn. of cefpodoxime acid
CA2584128C (en) Process for producing penam compound
JPS58213788A (en) Ampicillin and amoxicillin derivative having alpha-lactamase inhibitor
CA2099692C (en) Process for preparing cephalosporin intermediates
US7273935B2 (en) Process for the preparation of 3-methylcepham derivatives
US20030199712A1 (en) Process for the preparation of cephalosporin intermediate and its use for the manufacture of cephalosporin compounds
NO168248B (en) PROCEDURE FOR DEOXYGENATION OF CEPHALOSPORIN-1BETA AND / OR CEPHALOSPORIN-1ALFA OXYDS.
CN101245078B (en) Benzathine salt of ceftiofur, preparation method and application thereof
CN108084212A (en) A kind of preparation method of Cefditoren pivoxil Cephalosporins
KR20010037039A (en) Method of preparing 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid
CN108299470B (en) Preparation method of cefteram pivoxil
KR20050035178A (en) A process for the preparation of cefixime via alkyl-or aryl-sulfonates
CN1237178A (en) Novel &#39;beta&#39;-lactam compounds and process for preparing the same
US4560749A (en) Cephem-3-imidates and 3-amidines
US20060009639A1 (en) Process for the preparation of cefpodoxime proxetil
CA1095025A (en) Process for preparing 2-acyloxymethylpenams and 3- acyloxy-cephams
CN101638412B (en) Cefepime hydrochloride compound prepared by new synthetic method
EP1704153A2 (en) Improved process for the production of cefotaxime sodium
CA1056816A (en) Process for the conversion of 6-aminopenicillanic acid (6-apa) in 7-aminodesacetoxycephalosporanic acid (7-adca)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070516

Termination date: 20091123